Leire Burgos
A5021425946- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Single-cell and spatial transcriptomics
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Chemokine receptors and signaling
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Peptidase Inhibition and Analysis
- PI3K/AKT/mTOR signaling in cancer
- Biosimilars and Bioanalytical Methods
- Chronic Myeloid Leukemia Treatments
- Renal Diseases and Glomerulopathies
- Lymphoma Diagnosis and Treatment
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Biomedical Ethics and Regulation
- Viral-associated cancers and disorders
- Advanced biosensing and bioanalysis techniques
- Hematopoietic Stem Cell Transplantation
- SARS-CoV-2 and COVID-19 Research
- Immune cells in cancer
- Acute Lymphoblastic Leukemia research
Clinica Universidad de Navarra
2016-2025
Navarre Institute of Health Research
2016-2025
Centro de Investigación Biomédica en Red de Cáncer
2017-2025
Universidad de Navarra
2012-2024
Instituto de Investigación Biomédica de Salamanca
2024
Centro de Investigación Biomédica en Red
2021
Universidade de São Paulo
2015
Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine applicability and sensitivity MRD-negative criterion defined International Myeloma Working Group (IMWG).In PETHEMA/GEM2012MENOS65 trial, 458 patients newly diagnosed MM had longitudinal assessment after six induction cycles bortezomib,...
PURPOSE Patients with multiple myeloma (MM) may show patchy bone marrow (BM) infiltration and extramedullary disease. Notwithstanding, quantification of plasma cells (PCs) continues to be performed in BM since the clinical translation circulating tumor (CTCs) remains undefined. PATIENTS AND METHODS CTCs were measured peripheral blood (PB) 374 patients newly diagnosed MM enrolled GEM2012MENOS65 GEM2014MAIN trials. Treatment included bortezomib, lenalidomide, dexamethasone induction followed...
Here, we investigated for the first time frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) newly diagnosed patients with localized systemic cell neoplasms (PCN) using next-generation flow cytometry (NGF) correlated our findings distinct diagnostic prognostic categories disease. Overall, 508 samples from 264 PCN patients, were studied. CTPC detected PB all active multiple myeloma (MM; 100%), smoldering MM (SMM) (100%), more than half (59%) monoclonal...
Light chain (AL) amyloidosis is caused by a small B-cell clone producing light chains that form amyloid deposits and cause organ dysfunction. Chemotherapy aims at suppressing the production of toxic (LC) restore function. However, even complete hematologic response (CR), defined as negative serum urine immunofixation normalized free LC ratio, does not always translate into response. Next-generation flow (NGF) cytometry used to detect minimal residual disease (MRD) in multiple myeloma. We...
Precise classification of acute leukemia (AL) is crucial for adequate treatment. EuroFlow has previously designed an AL orientation tube (ALOT) to guide towards the relevant panel (T-cell lymphoblastic (T-ALL), B-cell precursor (BCP)-ALL and/or myeloid (AML)) and final diagnosis. Now we built a reference database with 656 typical samples (145 T-ALL, 377 BCP-ALL, 134 AML), processed analyzed via standardized protocols. Using principal component analysis (PCA)-based plots automated algorithms...
Large-scale immune monitoring is becoming routinely used in clinical trials to identify determinants of treatment responsiveness, particularly immunotherapies. Flow cytometry remains one the most versatile and high throughput approaches for single-cell analysis; however, manual interpretation multidimensional data poses a challenge when attempting capture full cellular diversity provide reproducible results. We present FlowCT, semi-automated workspace empowered analyze large sets. It...
The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present a monoclonal gammopathy undetermined significance (MGUS)-like phenotype has been hypothesized, but methods to identify this subgroup are not standardized its clinical is properly validated.An algorithm having MGUS-like was developed on the basis percentages total bone marrow (BM) plasma cells (PC) clonal PC within BM compartment, determined at diagnosis using flow cytometry in 548 MGUS 2,011...
Precise classification of acute leukemia (AL) is crucial for adequate treatment. EuroFlow has previously designed an AL orientation tube (ALOT) to guide toward the relevant panel and final diagnosis. In this study, we validated algorithm automated (database-supported) gating identification (AGI tool) cell subsets within samples stained with ALOT. A reference database normal peripheral blood (PB, n = 41) bone marrow (BM; 45) analyzed ALOT was constructed, served as a AGI tool automatically...
There is evidence of reduced SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies. We hypothesized that tumor and treatment-related immunosuppression can be depicted peripheral blood, immune profiling prior to vaccination help predict immunogenicity. performed a comprehensive immunological characterization 83 before measured IgM, IgG, IgA antibody response four viral antigens at day +7 after second-dose COVID-19 using multidimensional computational flow cytometry....